Can we really believe that aprotinin is safe in congenital heart surgery?

Annals of Thoracic Surgery

Volumn 91, Issue 3, 2011, Pages 987-988

  Faraoni, David ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

BLEEDING; BLOOD TRANSFUSION; CONGENITAL HEART DISEASE; DRUG SAFETY; HEART SURGERY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LETTER; MORBIDITY; PRIORITY JOURNAL; SURGICAL MORTALITY;

EID: 79951977022     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2010.07.106     Document Type: Letter

References (3)

1. S.K. Pasquali, M. Hall, and J.S. Li Safety of aprotinin in congenital heart operations: results from a large multicenter database Ann Thorac Surg 90 2010 14 21
2. D.A. Fergusson, P.C. Hebert, and C.D. Mazer A comparison of aprotinin and lysine analogues in high-risk cardiac surgery N Engl J Med 358 2008 2319 2331 (Pubitemid 351749156)
3. E.S. Schouten, A.C. van de Pol, A.N.J. Schouten, N.M. Turner, N.J.G. Jansen, and C.W. Bollen The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: a meta-analysis Pediatr Crit Care Med 10 2009 182 190